ReviewInternational journal of radiation oncology, biology, physics2021
Single- and Multifraction Stereotactic Radiosurgery Dose/Volume Tolerances of the Brain.
Review in International journal of radiation oncology, biology, physics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07415668 (Motor Eloquent Navigated Transcranial Magnetic Stimulation for Radiosurgery Planning), which is not on this map. Cited by 219 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Motor Eloquent Navigated Transcranial Magnetic Stimulation for Radiosurgery Planning
Who cites it
219 citing papers in PubMed, 2 syntheses or guidelines pooled it, 369 citations in OpenAlex.
- Effects of concurrent HER2-directed therapy on development of cerebral radionecrosis after stereotactic radiotherapy: a systematic review.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Pooled it
- Pooled it
- Personalized machine learning-guided radiation dose escalation in newly diagnosed glioblastoma: prospective pilot study.Nature communications · 2026Trial
- Efficacy and safety of combining bevacizumab and fractionated stereotactic radiotherapy for extensive brain metastases in patients with non-small cell lung cancer: a prospective phase II study (GASTO-1053).Cancer communications (London, England) · 2025Trial
- SAFESTEREO: phase II randomized trial to compare stereotactic radiosurgery with fractionated stereotactic radiosurgery for brain metastases.BMC cancer · 2023Trial
- Reirradiation of recurrent brain tumors: a review by the ESTRO CNS Focus Group.Clinical and translational radiation oncology · 2027Review
- LINAC-based single-isocenter stereotactic radiotherapy for multiple brain metastases.Journal of radiation research · 2026Article
- Perivascular spaces as MRI markers associated with radiation necrosis in brain metastases patients: an exploratory study.Neuroradiology · 2026Article
- Target-volume-based prescription selection for specified adverse-effect levels in automated stereotactic radiosurgery.Physics and imaging in radiation oncology · 2026Article
- Evaluation of EPID-Based Transmission and DLG Correction Methods for Dosimetric Verification in HyperArc Single-Isocenter Multiple Target Radiosurgery.Diagnostics (Basel, Switzerland) · 2026Article
- Stereotactic radiotherapy in brain metastases: SRS/FSRT paradox and preferences of radiation oncologists in Türkiye (TROD 10-010 study).Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Stereotactic radiotherapy using a linear accelerator for arteriovenous malformation and arteriovenous fistula identification using 320-row angiography-computed tomography images, case series and a single-center experience.Fujita medical journal · 2026Article
- Initial Experience With Stereotactic Radiosurgery for Refractory Trigeminal Neuralgia Using the OXRAY System.Cureus · 2026Article
- Outcomes of hypofractionated stereotactic radiotherapy for brain metastases: do we treat patients or lesions?BMC cancer · 2026Article
- Multimodal therapy for ovarian cancer with brain metastases diagnosed synchronously at the initial phase: case report of a long-term survivor with comprehensive literature review.Gynecologic oncology reports · 2026Article
- Radiotherapy for Vestibular Schwannoma: Retrospective Cohort and Propensity Score Matching Analysis.Journal of neurological surgery. Part B, Skull base · 2026Article
- Cerebral Radionecrosis Following Stereotactic Irradiation of Skull Bone Metastases: A Diagnostic Pitfall to Be Aware of.Diagnostics (Basel, Switzerland) · 2026Article
- Development and validation of a knowledge-based model for robotic radiosurgery planning for brain lesions.Physics and imaging in radiation oncology · 2026Article
- Article
- Incidence of radiation necrosis following different radiotherapy fractionation schedules for intracranial meningiomas.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
159 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 2 countries.
Funding
Abstract
purposeAs part of the American Association of Physicists in Medicine Working Group on Stereotactic Body Radiotherapy investigating normal tissue complication probability (NTCP) after hypofractionated radiation therapy, data from published reports (PubMed indexed 1995-2018) were pooled to identify dosimetric and clinical predictors of radiation-induced brain toxicity after single-fraction stereotactic radiosurgery (SRS) or fractionated stereotactic radiosurgery (fSRS). METHODS AND MATERIALS: Eligible studies provided NTCPs for the endpoints of radionecrosis, edema, or symptoms after cranial SRS/fSRS and quantitative dose-volume metrics. Studies of patients with only glioma, meningioma, vestibular schwannoma, or brainstem targets were excluded. The data summary and analyses focused on arteriovenous malformations (AVM) and brain metastases.
resultsData from 51 reports are summarized. There was wide variability in reported rates of radionecrosis. Available data for SRS/fSRS for brain metastases were more amenable to NTCP modeling than AVM data. In the setting of brain metastases, SRS/fSRS-associated radionecrosis can be difficult to differentiate from tumor progression. For single-fraction SRS to brain metastases, tissue volumes (including target volumes) receiving 12 Gy (V12) of 5 cm
conclusionsThe risk of radionecrosis after SRS and fSRS can be modeled as a function of dose and volume treated. The use of fSRS appears to reduce risks of radionecrosis for larger treatment volumes relative to SRS. More standardized dosimetric and toxicity reporting is needed to facilitate future pooled analyses that can refine predictive models of brain toxicity risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.